Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

74.19 -0.12 (-0.16%)
Official Closing Price Updated: 4:15 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 Next >
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
 
Via Benzinga
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch. 
Via Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors. 
Via Chartmill
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings. 
Via Chartmill
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Preview: Mirum Pharmaceuticals's Earnings
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum
Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching. 
Via Chartmill
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock
 
Via Benzinga
FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish
Livmarli tablets will be available in June through Mirum Access Plus pharmacy. 
Via Stocktwits
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol
Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million. 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Earnings Outlook For Mirum Pharmaceuticals
 
Via Benzinga
Analyst Expectations For Mirum Pharmaceuticals's Future
 
Via Benzinga
We Tested Top Stocks; Here’s What’s Best For Your Money
Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities. 
Via Talk Markets
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Analyst Ratings For Mirum Pharmaceuticals
 
Via Benzinga
Analyst Ratings For Mirum Pharmaceuticals
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and... 
Via Benzinga
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.